NCT04349683View on ClinicalTrials.gov

Efficacy and Safety of Jinshuibao for Patients With Chronic Kidney Disease Due to Glomerulonephritis

PHASE4UnknownINTERVENTIONAL
Enrollment

332

Participants

Timeline

Start Date

April 30, 2020

Primary Completion Date

August 30, 2021

Study Completion Date

October 30, 2021

Conditions
Chronic Kidney Disease Stage 3BChronic Kidney Disease stage4Glomerulonephritis
Interventions
DRUG

Jinshuibao

6 capsules at a time, 3 times a day (tid).

DRUG

Placebo

6 capsules at a time, 3 times a day (tid).

Sponsors

Lead Sponsor

Jemincare
All Listed Sponsors
collaborator

Shanghai 6th People's Hospital

OTHER

lead

Jemincare

INDUSTRY

NCT04349683 - Efficacy and Safety of Jinshuibao for Patients With Chronic Kidney Disease Due to Glomerulonephritis | Biotech Hunter | Biotech Hunter